UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

Mark One

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September~~March 3031, ~~2025~~ 2026

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. 333-234487

BIOSCIENCE HEALTH INNOVATIONS INC.

(Exact name of registrant as specified in its charter)

Nevada	7374	98-1498782
(State or Other Jurisdiction of	(Primary Standard Industrial	(IRS Employer
Incorporation or Organization)	Classification Number)	Identification Number)

~~2722~~ 14857 South ~~West~~Concord ~~Temple~~Park Drive

~~Salt Lake City~~Bluffdale, UT ~~84115~~84065

(Address of principal executive offices)

Registrant’s telephone number, including area code: (801) 949-0791

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
None		None		None

Securities registered pursuant to Section 12(g) of the Act: Common stock, par value $0.0001

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated Filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the practicable date:

Class		Outstanding as of ~~October~~May 248, ~~2025~~2026
Common Stock: $0.0001 par value		1011,~~979~~416,~~055~~125

TABLE OF CONTENTS

PART I	FINANCIAL INFORMATION
PART 1 FINANCIAL INFORMATION
Item 1.	~~Financial Statements~~	3Financial Statements	3
	~~Condensed Consolidated Balance Sheets (unaudited)~~	4Condensed Consolidated Balance Sheets (unaudited)	4
	~~Condensed Consolidated Statements of Operations (unaudited)~~	5Condensed Consolidated Statements of Operations (unaudited)	5
	~~Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (unaudited)~~	6Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (unaudited)	6
	~~Condensed Consolidated Statements of Cash Flows (unaudited)~~	7Condensed Consolidated Statements of Cash Flows (unaudited)	7
	~~Notes to Financial Consolidated Statements (unaudited)~~	8Notes to Financial Consolidated Statements (unaudited)	8
Item 2.	~~Management’s Discussion and Analysis of Financial Condition and Results of Operations~~	13Management’s Discussion and Analysis of Financial Condition and Results of Operations	13
Item 3.	~~Quantitative and Qualitative Disclosures About Market Risk~~	19Quantitative and Qualitative Disclosures About Market Risk	19
Item 4.	~~Controls and Procedures~~	19Controls and Procedures	19
PART II	OTHER INFORMATION
PART II OTHER INFORMATION
Item 1.	~~Legal Proceedings~~	20Legal Proceedings	20
Item 1A.	~~Cybersecurity~~	20Cybersecurity	20
Item 2.	~~Unregistered Sales of Equity Securities and Use of Proceeds~~	20Unregistered Sales of Equity Securities and Use of Proceeds	20
Item 3.	~~Defaults Upon Senior Securities~~	20Defaults Upon Senior Securities	20
Item 4.	~~Mine Safety Disclosures~~	20Mine Safety Disclosures	20
Item 5.	~~Other Information~~	20Other Information	20
Item 6.	~~Exhibits~~	21Exhibits	21
	~~Signatures~~	22Signatures	22

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

While the information presented in the accompanying financial statements is unaudited, it includes all adjustments which are, in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows for the periods presented in accordance with the accounting principles generally accepted in the United States of America (“US GAAP”). In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. Certain information and footnote disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted. These financial statements should be read in conjunction with the Company’s December 31, ~~2024~~2025 audited financial statements and notes thereto. Operating results for the ~~nine~~ three months ended ~~September~~March 3031, ~~2025~~2026 are not necessarily indicative of the results that can be expected for the year ending December 31, ~~2025~~2026.

Table of Contents

BIOSCIENCE HEALTH INNOVATIONS, INC ~~(FORMERLY NOWTRANSIT INC~~.

CONDENSED CONSOLIDATED BALANCE SHEETS

	September 30,		December 31,
	March 31,		December 31,
	2025		2024
	2026		2025
	(Unaudited)
ASSETS
Current Assets
Cash and cash equivalents	$	1,~~139~~145,~~423~~005	$	~~662~~661,~~517~~925
Accounts receivable, net		6378,~~212~~278		~~100~~399,~~285~~257
Inventory		~~757~~874,~~500~~340		58336,~~319~~348
Prepaid expense		3495,~~864~~146		421,~~832~~341
Overpayment to related parties		-		21137,~~798~~718
Total current assets		1,994,999		847,751
Deferred tax asset		2,069		2,069
Total current assets		2,194,838		1,558,658
Other Assets
Intangible assets		7282,~~101~~887		2682,~~037~~887
Total Assets	$	2,067,100	$	873,788
Deposits		4,400		4,400
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Right -of-use asset		48,114		61,236
Total other assets		135,401		148,523
Total Assets	$	2,330,239	$	1,707,181
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current Liabilities
Accounts payable	$	106,~~165~~787	$	86,~~226~~274
Due to related parties		228,298		-
Accrued expenses		22,781		7,957
Accrued expenses		6,686		5,993
Income tax payable		79,030		79,030
Deferred revenue		~~110~~76,~~991~~749		24136,~~329~~590
Total current liabilities		356,140		38,548
Note payable		460,402		-
STOCKHOLDERS' EQUITY (DEFICIT)
Total current liabilities		645,749		229,851
Preferred stock: $0.0001 par value, 5,000,000 shares authorized;		-		-
STOCKHOLDERS’ EQUITY (DEFICIT)
Series A Convertible Preferred Stock, 1,000,000 designated, 140,000 shares issued and outstanding at September 30, 2025 and December 31, 2024		14		14
Preferred stock: $0.0001 par value, 5,000,000 shares authorized;
Common stock: $0.0001 par value, 250,000,000 shares authorized; 10,979,055 shares issued and outstanding at September 30, 2025 and December 31, 2024		1,098		1,098
Series A Convertible Preferred Stock, 1,000,000 designated, 140,000 shares issued and outstanding at March 31, 2026 and December 31, 2025		14		14
Additional paid-in capital		1,175,211		1,175,211
Common stock: $0.0001 par value, 250,000,000 shares authorized; 11,416,125 and 10,979,058 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively		1,142		1,098
Accumulated earnings (deficit)		534,637		(341,083	)
Additional paid-in capital		1,612,234		1,175,211
Total stockholders' equity (deficit)		1,710,960		835,240
Accumulated earnings (deficit)		71,100		301,007
Total Liabilities and Stockholders' Equity (Deficit)	$	2,067,100	$	873,788
Total stockholders’ equity (deficit)		1,684,490		1,477,330
Total Liabilities and Stockholders’ Equity (Deficit)	$	2,330,239	$	1,707,181

See accompanying notes to the unaudited condensed consolidated financial statements.

Table of Contents

BIOSCIENCE HEALTH INNOVATIONS, INC ~~(FORMERLY NOWTRANSIT INC~~.)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	For the Three Months Ended						~~For the Nine Months Ended~~
	September 30,						September 30,
	March 31,
	2025			2024			2025			2024
	2026			2025
Revenues	$	1750,~~131,427~~946		$	~~572~~1,~~973~~227,070		$	~~4,115,960~~		$	~~1,234,744~~
Cost of goods sold		(~~433~~265,~~196~~350	)		(~~148~~330,~~233~~925	)		~~(1,447,106~~	)		~~(264,865~~	)
Gross profit		698,231			424,740			2,668,854			969,879
Gross Profit		485,596			896,145
Operating Expenses:
General and administrative expenses		~~576~~625,~~656~~809			~~345~~433,~~288~~561			~~1,550,291~~			~~846,236~~
Consulting fees		~~130~~89,~~357~~694			2335,~~250~~786			~~242,843~~			~~46,600~~
Total Operating Expenses		~~707~~715,~~013~~503			~~368~~469,~~538~~347			~~1,793,134~~			~~892,836~~
Income (Loss) from Operations		(8229,~~782~~907	)		56426,~~202~~798			~~875,720~~			~~77,043~~
Net Income (Loss)	$	(8,782	)	$	56,202		$	875,720		$	77,043
Income tax expense		-			-
Net loss per common share - basic	$	(0.00	)	$	0.01		$	0.08		$	0.01
Net Income (Loss)	$	(229,907	)	$	426,798
Net loss per common share - diluted	$	(0.00	)	$	0.01		$	0.08		$	0.01
Net income (loss) per common share - basic	$	(0.02	)	$	0.01
Weighted average common shares outstanding - basic		10,979,055			10,474,055			10,979,055			10,386,008
Net income (loss) per common share - diluted	$	(0.02	)	$	0.01
Weighted average common shares outstanding - diluted		10,979,055			10,894,055			11,399,055			10,806,008
Weighted average common shares outstanding - basic		11,376,802			43,916,221
Weighted average common shares outstanding - diluted		11,376,802			44,336,221

See accompanying notes to the unaudited condensed consolidated financial statements.

Table of Contents

BIOSCIENCE HEALTH INNOVATIONS, INC ~~(FORMERLY NOWTRANSIT INC~~.)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

FOR THE ~~NINE~~THREE MONTHS ENDED ~~SEPTEMBER~~MARCH 3031, ~~2025~~2026 AND ~~2024~~2025

(Unaudited)

	Series A Convertible								Additional		Accumulated
	Preferred Stock				Common Stock				Paid-in		Earnings
	Shares		Amount		Shares		Amount		Capital		(Deficit)			Total
Balance at December 31, 2023		140,000	$	14		10,224,055	$	1,022	$	420,287	$	(428,083	)	$	(6,760	)
Balance at December 31, 2024		140,000	$	14		10,979,058	$	1,098	$	1,175,211	$	(341,083	)	$	835,240
Common shares issued for cash		-		-		175,000		18		174,982		-			175,000
Net loss		-		-		-		-		-		426,798			426,798
Net loss		-		-		-		-		-		(53,381	)		(53,381	)
Balance at March 31, 2025		140,000	$	14		10,979,058	$	1,098	$	1,175,211	$	85,715		$	1,262,038
Balance at March 31, 2024		140,000		14		10,399,055		1,040		595,269		(481,464	)		114,859
Balance at December 31, 2025		140,000	$	14		10,979,058	$	1,098	$	1,175,211	$	301,007		$	1,477,330
Net income		-		-		-		-		-		74,222			74,222
Common shares issued for cash		-		-		437,067		44		437,023		-			437,067
Balance at June 30, 2024		140,000		14		10,399,055		1,040		595,269		(407,242	)		189,081
Net loss		-		-		-		-		-		(229,907	)		(229,907	)
Common shares issued for cash		-		-		125,000		13		124,987		-			125,000
Balance at March 31, 2026		140,000	$	14		11,416,125	$	1,142	$	1,612,234	$	71,100		$	1,684,490
Net income		-		-		-		-		-		56,202			56,202
Balance at September 30, 2024		140,000	$	14		10,524,055	$	1,053	$	720,256	$	(351,040	)	$	370,283
Balance at December 31, 2024		140,000	$	14		10,979,055	$	1,098	$	1,175,211	$	(341,083	)	$	835,240
Net income		-		-		-		-		-		426,798			426,798
Balance at March 31, 2025		140,000		14		10,979,055		1,098		1,175,211		85,715			1,262,038
Net income		-		-		-		-		-		457,704			457,704
Balance at June 30, 2025		140,000		14		10,979,055		1,098		1,175,211		543,419			1,719,742
Net loss		-		-				-		-		(8,782	)		(8,782	)
Balance at September 30, 2025		140,000	$	14		10,979,055	$	1,098	$	1,175,211	$	534,637		$	1,710,960

See accompanying notes to the unaudited condensed consolidated financial statements.

Table of Contents

BIOSCIENCE HEALTH INNOVATIONS, INC ~~(FORMERLY NOWTRANSIT INC~~.)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	For the Nine Months Ended
	For the Three Months Ended
	September 30,
	March 31,
	2025			2024
	2026			2025
	(unaudited)
Cash Flows From Operating Activities
Net Income (Loss)	$	~~875~~(229,~~720~~907	)	$	77426,~~043~~798
Adjustments to reconcile net loss to net cash used in operating activities		-			-
Adjustments to reconcile net income (loss) to net cash used in operating activities
Lease cost, net of repayments		13,122			-
Changes in operating assets and liabilities:
Accounts receivable		37320,~~073~~979			46,~~535~~836
Inventory		(~~699~~537,~~181~~992	)		(4157,~~523~~377	)
Deferred revenue		86(59,~~662~~841	)		(325,~~949~~709	)
Accrued services		693			1,050
Accrued expenses		14,824			14,757
Accounts payable		~~1,939~~513			~~772~~8,189
Prepaid expenses		(3073,~~032~~805	)		(13,~~435~~397	)
Net Cash Provided by (Used in) Operating Activities		~~272~~(552,~~874~~107	)		73328,~~493~~309
Cash Flows From Investing Activities
Purchase of intangible assets		~~(46,064~~-	)		(730,~~037~~000	)
Net Cash Used in Investing Activities		~~(46,064~~-	)		(730,~~037~~000	)
Cash Flows From Financing Activities
Advances from related parties		2748,~~422,096~~120			~~692~~589,~~746~~516
Repayment to related parties		(2150,~~172,~~000	)		(~~745~~522,~~220~~000	)
Proceeds from the sale of common stock		-437,067			~~300,000~~-
Net Cash Provided by Financing Activities		~~250~~1,~~096~~035,187			~~247~~67,~~526~~516
Net Increase in Cash		~~476~~483,~~906~~080			~~313~~365,~~982~~825
Cash at Beginning of Period		~~662~~661,~~517~~925			19662,~~238~~517
Cash at End of Period	$	1,~~139~~145,~~423~~005		$	~~333~~1,~~220~~028,342
Supplemental Cash Flow Information:
Cash paid for interest	$	-		$	-
Cash paid for income taxes	$	-		$	-
Non-Cash Investing and Financing Activities:
Note payable issued for related party debt	$	460,402		$	-

See accompanying notes to the unaudited condensed consolidated financial statements.

Table of Contents

BIOSCIENCE HEALTH INNOVATIONS INC (FORMALY KNOWN AS NOWTRANSIT INC.)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~September 30~~March 31, ~~2025~~2026

(Unaudited)

Note 1 - Nature of Organization

Nowtransit Inc. (the “Company,” “us,” “we,” “Nowtransit”) was incorporated in the State of Nevada on July 8, 2019, and changed its name to BioScience Health Innovations Inc on February 21, 2025. Through March 10, 2023 we had no operations and had not generated any material revenues since inception. Effective March 10, 2023, we closed on a Share Exchange Agreement with Best 365 Labs Inc. (“Best”), a Nevada corporation, wherein we acquired all of the shares of Best and Best became a wholly owned subsidiary of the Company.

Best was incorporated on October 12, 2021 in the State of Nevada. Best sells clinically-tested, affordably priced products to naturally battle the onslaught of bacteria and viruses through online sales and in various other distribution channels. ~~Presently,~~in the Company is selling Be On-Guard Mouth Spray, Be On-Guard Nasal Spray, Be On-Guard Brain Fog Support, ADHD 365 maximum brain support, EZ Safer Surface Cleaner, NeuroPro Plus a patent pending combination of pharmaceutical grade methylene blue and vitamin C, TBI-365 to elevate your brain health and wellness ~~with pharmaceutical grade methylene blue, glucine, nac and niacinamide and Metabolism+ to enhance your metabolism~~market.

Note 2 - ~~Going Concern~~Liquidity

The condensed consolidated financial statements have been prepared onin aaccordance ~~going~~with ~~concern~~US ~~basis~~generally ~~which~~accepted accounting principles, which assumes that the Company’s management will ~~continue~~evaluate aswhether ait ~~going~~will ~~concern,~~be ~~which~~able ~~contemplates continuity~~to ofmeet ~~operations,~~its ~~realization~~obligations ~~of assets,~~ and ~~liquidation~~continue ofits ~~liabilities~~ operations in the normal course of business.

AsThe Company ~~reflected~~had innet ~~the~~income ~~condensed~~of ~~consolidated~~$642,090 ~~financial~~and ~~statements~~positive cash provided by operating activities of $172,178 for the ~~Company~~year ~~has~~ended ~~generated~~December ~~revenues~~31, ~~resulting~~2025. inWhile the Company had a net ~~income~~loss of $229,907 during the ~~nine~~three months ended ~~September~~March 3031, ~~2025~~2026, ~~resulting~~ inthey recorded accumulated earnings of $~~534~~71,~~637~~100, had asnet ofworking ~~September~~capital 30of $1,549,089, ~~2025.~~and ~~However~~reported cash of $1,145,005 inas ~~the~~of ~~past~~March ~~the~~31, ~~Company~~2026, ~~has~~which ~~reported~~management ~~losses~~believes ~~and~~is ~~cash~~sufficient ~~used~~to inmeet ~~operating~~its ~~activities~~obligations ~~and~~over ~~has~~the ~~relied~~next onyear. ~~advances~~These ~~from~~financial ~~related~~statements ~~parties~~do ~~and~~not ~~proceeds~~include ~~from~~any ~~the~~adjustments ~~sale~~relating ofto ~~stock,~~the ~~therefore~~recoverability and ~~has~~classification ~~not~~of ~~yet developed~~recorded aasset ~~proven~~amounts ~~track~~and ~~record~~classification of ~~profitability.~~liabilities ~~These~~that ~~factors~~might ~~raise~~be ~~substantial~~necessary ~~doubt~~should ~~about~~ the Company’s ~~ability~~determine it shall be unable to continue as a going concern.

The Company is engaged in full-scale operations and generates sufficient revenue; however, the Company’s cash position may not be sufficient to support the Company’s daily operations long-term. Management intends to raise additional funds by way of a private or public offering. While the Company believes in the viability of its strategy to commence operations and generate sufficient revenue and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds by way of a public or private offering.8

8Table of Contents

~~Table~~Note 3 - Summary of ~~Contents~~Significant Accounting Policies

~~Note 3 - Summary~~ Basis of ~~Significant Accounting Policies~~Presentation

~~Basis~~The accompanying unaudited condensed consolidated financial statements of ~~Presentation~~the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and with the rules and regulations of the Securities and Exchange Commission, including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with US GAAP, have been condensed or omitted from these statements and should be read in conjunction with our audited financial statements. The financial statements are presented in US dollars and the Company has adopted a December 31 year end.

~~The accompanying unaudited condensed~~Use ~~consolidated financial statements~~ of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and with the rules and regulations of the Securities and Exchange Commission, including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with US GAAP, have been condensed or omitted from these statements and should be read in conjunction with our audited financial statements. The financial statements are presented in US dollars and the Company has adopted a December 31 year end.Estimates

~~Use~~The preparation of ~~Estimates~~financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses. Actual results could differ from those estimates.

~~The preparation of financial statements~~Segment in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses. Actual results could differ from those estimates.Reporting

~~Segment~~The Company ~~Reporting~~operates as a single operating and reportable segment as a retailer selling mental health and general wellness products. Our Chief Executive Officer, who serves as our Chief Operating Decision Maker (“CODM”), evaluates the Company’s financial performance and makes resource allocation decisions considering our one geographical area and on a consolidated basis. Accordingly, the CODM considers the revenue, operating expenses, and other income (expenses) of our single operating segment as reported on the statement of operations and considers our current and total assets as recorded on the balance sheet. There are no additional expense or asset information that are supplemental to those disclosed in these condensed consolidated financial statements that are regularly provided to the CODM.

~~The Company operates as a single operating~~Cash and ~~reportable~~Cash segment as a retailer selling mental health and general wellness products. Our Chief Executive Officer, who serves as our Chief Operating Decision Maker (“CODM”), evaluates the Company’s financial performance and makes resource allocation decisions considering our one geographical area and on a consolidated basis. Accordingly, the CODM considers the revenue, operating expenses, and other income (expenses) of our single operating segment as reported on the statement of operations and considers our current and total assets as recorded on the balance sheet. There are no additional expense or asset information that are supplemental to those disclosed in these condensed consolidated financial statements that are regularly provided to the CODM. Equivalents

Cash and cash equivalents include cash on hand, cash in banks and ~~Cash~~any ~~Equivalents~~highly liquid investments with a maturity of three months or less to the extent the funds are not being held for investment purposes. As of March 31, 2026 and December 31, 2025, the Company had no cash equivalents.

~~Cash and cash equivalents include cash~~The onCompany ~~hand,~~maintains ~~cash~~four inaccounts ~~banks~~at ~~and~~Wells ~~any~~Fargo ~~highly~~Bank. ~~liquid~~Accounts ~~investments~~at ~~with~~this ainstitution ~~maturity~~are ofinsured ~~three~~by ~~months or less to~~ the ~~extent~~Federal ~~the~~Deposit ~~funds~~Insurance ~~are not being~~Corporation ~~held~~up ~~for~~to ~~investment purposes~~$250,000. As of ~~September~~March 3031, ~~2025~~2026 ~~and~~the ~~December~~Company ~~31,~~has ~~2024,~~balances ~~the~~of ~~Company~~$644,904 ~~had~~in noexcess ~~cash~~of ~~equivalents~~this limit.

~~The Company maintains four accounts at Wells Fargo Bank.~~ Accounts ~~at this institution are insured by the Federal~~ ~~Deposit~~Receivable ~~Insurance~~and ~~Corporation~~Allowance upfor toDoubtful ~~$250,000. As of September 30, 2025 the Company has balances of $638,960 in excess of this limit.~~Accounts

~~Accounts~~The Company ~~Receivable~~reviews accounts receivable periodically for collectability and ~~Allowance~~establishes an allowance for doubtful accounts and records bad debt expense when deemed necessary. The Company records an allowance for ~~Doubtful~~doubtful accounts that is based on historical trends, customer knowledge, any known disputes, and considers the aging of the accounts receivable balances combined with management’s estimate of future potential recoverability. Accounts and receivables are written off against the allowance after all attempts to collect a receivable have failed. As of March 31, 2026 and December 31, 2025, the allowance for doubtful accounts was $0.

The Company reviews accounts receivable periodically for collectability and establishes an allowance for doubtful accounts and records bad debt expense when deemed necessary. The Company records an allowance for doubtful accounts that is based on historical trends, customer knowledge, any known disputes, and considers the aging of the accounts receivable balances combined with management’s estimate of future potential recoverability. Accounts and receivables are written off against the allowance after all attempts to collect a receivable have failed. As of September 30, 2025 and December 31, 2024, the allowance for doubtful accounts was $0.Inventory

~~Inventory~~The Company’s inventory is recognized in accordance with Accounting Standards Codification (“ASC”) 303. The Company uses the lower of cost (determined using the first-in, first-out method) or net realizable value for valuing inventories. As of March 31, 2026 and December 31, 2025, the Company had $438,563 and $336,348 of finished goods on hand, respectively. And on March 31, 2026 and December 31, 2025, the Company had $435,777 and $0 of raw materials on hand respectively

~~The Company’s inventory is recognized~~Income in accordance with Accounting Standards Codification (“ASC”) 303. The Company uses the lower of cost (determined using the first-in, first-out method) or net realizable value for valuing inventories. As of September 30, 2025 and December 31, 2024, the Company had $757,500 and $58,319 of finished goods on hand, respectively.Taxes

~~Income~~The provision ~~Taxes~~for income taxes and deferred income taxes are determined using the asset and liability method. Deferred tax assets and liabilities are determined based on temporary differences between the financial carrying amounts and the tax basis of assets and liabilities using enacted tax rates in effect in the years in which the temporary differences are expected to reverse. On a periodic basis, the Company assesses the probability that its net deferred tax assets, if any, will be recovered. If after evaluating all of the positive and negative evidence, a conclusion is made that it is more likely than not that some portion or all of the net deferred tax assets will not be recovered, a valuation allowance is provided by a charge to tax expense to reserve the portion of the deferred tax assets which are not expected to be realized.

The provision for income taxes and deferred income taxes are determined using the asset and liability method. Deferred tax assets and liabilities are determined based on temporary differences between the financial carrying amounts and the tax basis of assets and liabilities using enacted tax rates in effect in the years in which the temporary differences are expected to reverse. On a periodic basis, the Company assesses the probability that its net deferred tax assets, if any, will be recovered. If after evaluating all of the positive and negative evidence, a conclusion is made that it is more likely than not that some portion or all of the net deferred tax assets will not be recovered, a valuation allowance is provided by a charge to tax expense to reserve the portion of the deferred tax assets which are not expected to be realized.9

9Table of Contents

~~Table of Contents~~Revenue Recognition

~~Revenue~~The ~~Recognition~~Company’s revenue is recognized in accordance with Accounting Standards Codification 606 and the Company sells products in the immune health supplement market. The Company’s performance obligation is to deliver product to customers therefore revenue is recognized once delivery occurs. Customers that are end users of the Company’s products will generally remit payment at the time of order placement, therefore payment received by the Company prior to product delivery is recorded as deferred revenue. Customers that are resellers of the Company’s products are offered credit terms and generally pay within 30-60 days. As of March 31, 2026 and December 31, 2025 deferred revenue was $76,749 and $136,590, respectively. Shipping and handling costs that occur are paid by the customer and is not recorded as revenue. The Company has a policy to provide a refund on any product returned by the customer and refunds are recorded as a reduction in revenue. Refunds have been minimal to date.

~~The Company’s revenue is recognized~~Advertising in accordance with Accounting Standards Codification 606 and operates in the immune health supplement market. The Company offers products – Be-OnGuard Nasal Spray used against nasal bacteria, viruses and allergens; Be-OnGuard Mouth Spray used against oral bacteria, viruses and allergens; and Be-OnGuard EZ Safer Air used against airborne bacteria, viruses and allergens; Be On-Guard Brain Fog Support; and ADHD 365 maximum strength brain support. The Company’s performance obligation is to deliver product to customers therefore revenue is recognized once delivery occurs. Customers will remit payment at the time of order placement, therefore payment received by the Company prior to product delivery is recorded as deferred revenue. As of September 30, 2025 and December 31, 2024 deferred revenue was $110,991 and $24,329. Shipping and handling costs that occur are paid by the customer and is not recorded as revenue. The Company has a policy to provide a refund on any product returned by the customer.Costs

Advertising costs ~~Costs~~are expensed as incurred. During the three months ended March 31, 2026 and 2025, the Company incurred advertising costs of $107,572 and $67,526, respectively.

~~Advertising costs are expensed as incurred. During the nine~~Research ~~months ended September 30, 2025~~ and ~~2024, the Company incurred advertising costs of $272,373 and $153,806, respectively.~~Development

~~Research~~The Company charges research and ~~Development~~development costs to expense when incurred. During the three months ended March 31, 2026 and 2025, the Company incurred $49,722 and $37,540 in research and development expenses, respectively.

~~The Company charges research and development costs to expense when incurred. During the nine~~Intangible ~~months ended September 30, 2025 and 2024, the Company incurred $66,372 and $29,808 in research and development expenses, respectively.~~Assets

~~Intangible~~The Company ~~Assets~~accounts for its intangible assets in accordance with ASC 350. Costs incurred to renew or extend the term of intangible assets are expensed as incurred. As of the three months ended March 31, 2026, the Company incurred $82,887 to file certain patent applications that showcase the Company’s innovative approach to health and wellness solutions. The patent costs were capitalized and will be amortized on a straight-line basis over its estimated useful life once the patents are granted. During the year ended December 31, 2025 and 2024 no amortization expense was recorded as the patents were still pending. Amortization expense of $4,144 for each year ended December 31, 2027 and beyond.

~~The Company accounts for its intangible assets in accordance with ASC 350. Costs incurred to renew or extend~~We ~~the~~have ~~term~~several ~~of intangible assets are expensed as incurred. As of the nine months ended September 30, 2025, the Company incurred $72,101 to file certain~~ patent applications ~~that~~pending ~~showcase~~in the ~~Company’s innovative approach to health and wellness solutions~~U. ~~The patent costs were capitalized and will be amortized on a straight-line basis over its estimated useful life once the patents are granted~~S. ~~During the year ended December 31, 2024~~ and ~~2023~~internationally ~~no amortization expense was recorded as the patents were still pending. Amortization expense of $901 is expected~~ for ~~the~~our ~~year~~innovative ~~ended~~methylithioninium ~~December~~(methylene ~~31,~~blue) ~~2025~~ and ~~$3,605 for each year ended~~mitochondrial ~~December~~health ~~31, 2026 and beyond.~~ compositions:

~~We have several patent applications~~Patent ~~pending~~Pending inProduct ~~the~~Overview ~~U.S.~~ and ~~internationally for our innovative methylithioninium (methylene blue) and mitochondrial health compositions:~~Update

U.S. Non-Provisional Patent ~~Pending~~Application ~~Product~~No. ~~Overview and~~18/931,277 ~~Update~~for METHYLTHIONINIUM SALT-CONTAINING COMPOSITIONS AND METHODS, filed on 10/30/2024

~~U.S. Non-Provisional~~ International Patent Application No. 18PCT/~~931,277~~US24/53487 for METHYLTHIONINIUM SALT-CONTAINING COMPOSITIONS AND METHODS, filed on 10/30/2024

~~International~~U.S. Non-Provisional Patent Application No. ~~PCT~~ 18/~~US24/53487~~931,346 for ~~METHYLTHIONINIUM SALT-CONTAINING~~ COMPOSITIONS AND ~~METHODS~~METHOD FOR SUPPORTING MITOCHONDRIAL, ~~filed~~file on 10/30/2024

~~U.S. Non-Provisional~~ International Patent Application No. 18PCT/~~931,346~~US24/53490 for COMPOSITIONS AND METHOD FOR SUPPORTING MITOCHONDRIAL, file on 10/30/2024. Filed on 10/30/2024

~~International~~U.S. Provisional Patent Application No. ~~PCT~~ 63/~~US24/53490~~712,895 for ~~COMPOSITIONS~~TREATMENTS ~~AND~~USING ~~METHOD~~METHYLTHIONINIUM ~~FOR~~SALT, ~~SUPPORTING~~SECONDARY ~~MITOCHONDRIAL,~~PHYSIOLOGICALLY ~~file~~ACTIVE onCOMPOUND ~~10/30/2024.~~AND PHYSIOLOGICAL ~~Filed~~THERAPY, filed on 10/3028/2024

U.S. Provisional Patent Application No. 63/~~712~~754,~~895~~434 for ~~TREATMENTS~~NUTRITIONAL ~~USING~~SUPPLEMENT ~~METHYLTHIONINIUM~~COMPOSITIONS ~~SALT,~~AND ~~SECONDARY~~METHODS ~~PHYSIOLOGICALLY~~FOR ~~ACTIVE~~ENHANCING ~~COMPOUND~~BIOLOGICAL ~~AND PHYSIOLOGICAL THERAPY~~FUNCTIONS, ~~filed~~ filed on 102/285/~~2024~~2025

~~U.S.~~All provisional ~~Provisional~~applications ~~Patent~~were ~~Application~~filed ~~No.~~with ~~19/173,875 for~~the ~~NUTRITIONAL~~U.S. ~~SUPPLEMENT~~Patent ~~COMPOSITIONS~~and ~~AND~~Trademark ~~METHODS~~Office ~~FOR~~by ~~ENHANCING~~Thorpe ~~BIOLOGICAL~~North ~~FUNCTIONS,~~and ~~filed on 4/9/2025~~Western.

~~All~~We believe ~~provisional~~these ~~applications~~filings ~~were~~cover ~~filed with~~multiple ~~the~~potential ~~U.S.~~patents ~~Patent~~ and ~~Trademark~~product ~~Office~~opportunities. byLeadership ~~Thorpe~~is ~~North~~actively exploring partnerships and ~~Western~~strategic alliances to maximize value for stakeholders.

~~We believe these filings cover multiple~~All ~~potential~~products ~~patents~~ and ~~product~~methods ~~opportunities.~~described ~~Leadership~~remain ispatent ~~actively~~pending ~~exploring~~as ~~partnerships~~of ~~and~~the ~~strategic~~date ~~alliances~~of tothis ~~maximize value for stakeholders~~filing.

~~All products and methods described remain patent pending as of the date of this filing.~~ 10

10Table of Contents

~~Table~~ Impairment of ~~Contents~~Long-lived Assets

The Company applies the provisions of ASC 360, where applicable, to all long-lived assets and periodically evaluates the carrying value of long-lived assets to be held and used for impairment. Impairment losses are recorded on long-lived assets used in operations when indicators of ~~Long~~impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. ~~Assets~~Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal. When long-lived assets are sold or retired, the related cost and accumulated depreciation or amortization are removed from the accounts and any gain or loss is included in the results of operations. During the three months ended March 31, 2026 and 2025, the Company recorded no impairment expense for their long-lived assets.

The Company applies the provisions of ASC 360, where applicable, to all long-lived assets and periodically evaluates the carrying value of long-lived assets to be held and used for impairment. Impairment losses are recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal. When long-lived assets are sold or retired, the related cost and accumulated depreciation or amortization are removed from the accounts and any gain or loss is included in the results of operations. During the nine months ended September 30, 2025 and 2024, the Company recorded no impairment expense for their long-lived assets.Leases

~~Leases~~The Company follows the provisions of ASC 842, and records right-of-use (“ROU”) assets and lease obligations for its operating leases, which are initially recognized based on the discounted future lease payments over the term of the lease. If the rate implicit in the Company’s leases is not readily determinable, the Company’s applicable incremental borrowing rate is used in calculating the present value of the sum of the lease payments. The lease term is defined as the non-cancelable period of the lease plus any options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option.

The Company ~~follows~~has ~~the~~elected ~~provisions of~~not ~~ASC~~to ~~842,~~recognize ~~and records right-of-use (“~~ROU”) ~~assets~~asset and lease obligations for its ~~operating~~short-term leases, which are ~~initially~~defined ~~recognized based~~as ~~on the discounted future lease payments over the term of the lease. If the rate implicit in the Company’s~~ leases iswith ~~not~~an ~~readily~~initial ~~determinable, the Company’s applicable incremental borrowing rate is used in calculating the present value of the sum of the lease payments. The lease~~ term ~~is defined as the non-cancelable period~~ of ~~the~~12 ~~lease~~months ~~plus any options to extend~~ or ~~terminate the lease when it is reasonably certain that the Company will exercise the option~~less.

~~The~~On December ~~Company~~1, ~~has~~2025, ~~elected~~we ~~not~~entered toa ~~recognize~~15-month rental arrangement for our office and inventory space, at which time we paid for the lease in full with a single payment of $65,610. Because there were no future lease payments to be made, we recorded an ROU asset at lease commencement for the value of the prepayment of $65,610 and had no lease ~~obligations~~liability ~~for~~to ~~its~~record. ~~short-term~~Before ~~leases~~December 1, ~~which~~2025, ~~are~~the ~~defined~~Company ashad ~~leases~~a ~~with~~month-to-month rental anagreement. ~~initial~~The ~~term~~Company recorded rent expense of 12$13,122 and $4,305, during the three months orended ~~less~~March 31, 2026 and 2025, respectively. As of March 31, 2026, the weighted average remaining lease term was 11 months.

~~During the nine months ended~~Net ~~September~~Income ~~30,~~(Loss) ~~2025~~per ~~and~~Common ~~2024, the Company had a month-to-month rental agreement for their office and inventory space and paid rent expense of $12,915.~~Share

Net income ~~Income~~(loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (~~Loss~~loss) per ~~Common~~common ~~Share~~share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially dilutive outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through contingent share arrangements, stock options and warrants. As of March 31, 2026 and 2025 there were dilutive securities of 420,000 for the conversion of Series A Convertible Preferred Stock. These potentially dilutive securities were not included in the calculation of diluted net loss per common share at March 31, 2026 because they were antidilutive, therefore as of March 31, 2026, basic and diluted weighted average common shares outstanding and net loss per common share are the same.

~~Net income (loss) per common share~~Recent ~~is computed pursuant to section 260-10-45 of the FASB~~ Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially dilutive outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through contingent share arrangements, stock options and warrants. As of September 30, 2025 and 2024 there were dilutive securities of 420,000 for the conversion of 140,000 shares of Series A Convertible Preferred Stock. Due to the net loss recorded for the three months ended September 30, 2025 all potentially dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share; therefore the basic and weighted average common shares outstanding and net loss per common share, basic and diluted, are the same.Pronouncements

~~Recent~~The Company ~~Accounting~~has ~~Pronouncements~~reviewed all the recent accounting pronouncements issued to date of the issuance of these financial statements and has determined that there have been no standards that had, or will have, a material impact on its consolidated financial statements with exception to the following:

~~The~~In November ~~Company~~2024, ~~has~~the ~~reviewed~~FASB ~~all~~issued ~~the~~ASU ~~recent~~2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic ~~accounting~~220-40): ~~pronouncements~~Disaggregation ~~issued~~of Income Statement Expenses, which requires incremental disclosures about specific expense categories, including but not limited to, ~~date~~purchases of ~~the~~inventory, ~~issuance~~employee ofcompensation, ~~these~~depreciation, ~~financial~~amortization ~~statements~~and selling expenses. The amendments are effective for fiscal years beginning after December 15, 2026, and ~~has~~for ~~determined~~interim ~~that~~periods ~~there~~within ~~have~~fiscal ~~been~~years nobeginning ~~standards that~~after ~~had~~December 15, 2027. Early adoption is permitted and the amendments may be applied either prospectively or ~~will~~retrospectively. ~~have,~~The aCompany ~~material~~is currently evaluating this ASU to determine its impact on ~~its~~the ~~consolidated~~Company’s ~~financial~~disclosures. ~~statements~~The ~~with~~amendments ~~exception~~only impact disclosures and are not expected to have an impact on the ~~following:~~Company’s financial condition and results of operations.

~~In November 2024, the FASB issued ASU~~Note ~~2024-03,~~4 ~~Income Statement~~ - ~~Reporting~~Related ~~Comprehensive~~Party Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires incremental disclosures about specific expense categories, including but not limited to, purchases of inventory, employee compensation, depreciation, amortization and selling expenses. The amendments are effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted and the amendments may be applied either prospectively or retrospectively. The Company is currently evaluating this ASU to determine its impact on the Company’s disclosures. The amendments only impact disclosures and are not expected to have an impact on the Company’s financial condition and results of operations.Transactions

~~Note~~During the 4three -months ~~Related~~ended ~~Party~~March ~~Transactions~~31, 2025 the Company purchased $456,556 worth of inventory from Ageless Holdings, LLC (“Holdings”), entity owned and controlled by the Company’s members of management and board of directors. Additionally, the Company received $132,960 worth of advances from Holdings to pay for operating expenses and the Company paid back $522,000 of the advances.

InDuring the ~~support~~three ofmonths ended March 31, 2026 the Company’s ~~efforts~~purchased $745,060 worth of inventory from Holdings, received $3,059 worth of advances ~~and~~from ~~cash~~Holdings ~~requirements~~to pay for operating expenses, itand ~~may~~paid ~~rely~~back on$150,000 of the advances. ~~from~~Additionally, ~~related~~during ~~parties~~the ~~until~~first ~~such~~quarter ~~time~~of ~~that~~2026 the Board ~~Company~~of ~~can~~Directors ~~support~~decided ~~its~~to ~~operations~~finalize ora ~~attains~~settlement agreement with Holdings and entered into a promissory note on March 28, 2026 for ~~adequate~~$460,402, ~~financing~~which ~~through~~was ~~sales~~equal ofto ~~its~~the ~~equity~~amount orowed ~~traditional~~to ~~debt~~them ~~financing~~as of that date. ~~Amounts~~The ~~represent~~note ~~advances~~carries oran ~~amounts~~interest ~~paid~~rate inof ~~satisfaction~~7% per annum, can be prepaid ofat ~~liabilities~~any time without penalty, and matures on December 31, 2026.

During the nine months ended September 30, 2025 the Company received advances of $2,422,096 from Ageless Holdings, LLC (“Ageless”), an entity owned and controlled by the Company’s members of management and board of directors, which included the purchase of $2,106,133 worth of inventory, $25,000 for services provided, and $290,693 to pay for operating expenses.11

~~During~~Table ~~the nine months ended September 30, 2024 the Company received advances~~ of ~~$692,746 from Ageless, which included the purchase of $285,463 worth of inventory from Ageless and $407,283 to pay for operating expenses. Additionally, the Company paid back $745,220 of the advances.~~Contents

11Note 5 - Equity

~~Table of Contents~~Common Stock

~~Note~~The 5Company -has ~~Equity~~250,000,000, $0.0001 par value shares of voting common stock authorized.

~~Common~~During the three months ended March ~~Stock~~31, 2026, the Company issued 437,067 shares in common stock for cash proceeds of $437,067.

~~The~~On September 10, 2025, the Company ~~has~~filed ~~250~~a change in the articles of incorporation and increased the voting common stock from 75,000,000, $0to 250,000,000.~~0001~~ ~~par~~In ~~value~~addition, ~~shares~~the Company completed a 1 for 4 reverse common stock split, decreasing the number of voting common stock outstanding ~~authorized~~from 43,916,221 to 10,979,058. All share numbers presented in these consolidated financial statements have been retroactively adjusted for the stock split.

During the ~~nine~~three months ended ~~September~~ 30March 31, 2025, there were no issuances of common stock.

OnAs ~~September~~of 10March 31, ~~the~~2026 ~~Company filed a change in the article of incorporation~~ and ~~increased~~December ~~the voting common stock authorized from 75~~31,~~000,000~~ ~~to 250~~2025,~~000,000.~~ ~~In addition,~~ the Company ~~completed~~had ~~a 1 for 4 reverse common stock split~~11, ~~decreasing the number of voting common stock outstanding from 43~~416,~~916,221 to~~125 and 10,979,~~055.~~058 ~~These~~shares ~~financial~~of ~~statements~~common ~~have~~stock ~~been~~issued ~~retroactively~~and ~~adjusted~~outstanding, ~~for all periods presented~~respectively.

~~During the three months ended September~~Preferred ~~30, 2024, the Company issued 125,000 shares of common stock for cash proceeds of $175,000.~~Stock

~~During~~On October 19, 2021, the ~~three~~Company ~~months~~filed ~~ended~~a ~~March~~Certificate of Amendment to its Articles of Incorporation authorizing up to 5,000,000 shares of 31Preferred Stock, ~~2024~~par value $0.0001 per share, with such rights, preferences and limitations as may be set forth in resolutions adopted by the Board of Directors. On November 1, 2021, the Company ~~issued~~filed ~~175~~a Certificate of Designation designating 1,000,000 shares of ~~common~~Preferred Stock ~~stock~~as ~~for~~Series ~~cash~~A ~~proceeds~~Convertible Preferred Stock (the “Series A”). Each share of ~~$175~~the Series A is convertible into three shares of the Company’s common stock at the holder’s election,~~000~~ subject to a 4.99% beneficial ownership limitation which may be increased to 9.99% upon 61 days’ notice.

During the three months ended March 31, 2026 and 2025 there were no issuances of preferred stock. As of ~~September~~March 3031, ~~2025~~2026 and December 31, ~~2024~~2025, the Company had 10140,~~979,055~~000 shares of ~~common~~Series ~~stock~~A ~~issued~~Convertible ~~and~~Preferred ~~outstanding,~~Stock ~~respectively~~outstanding.

~~Preferred~~Note ~~Stock~~6 - Subsequent Events

OnThe ~~October 19, 2021, the~~ Company ~~filed~~has aevaluated ~~Certificate~~all ofevents ~~Amendment~~that tooccur ~~its~~after ~~Articles~~the ofbalance ~~Incorporation~~sheet ~~authorizing~~date upthrough toApril 528,~~000,000~~ ~~shares of Preferred Stock~~2026, ~~par value $0.0001 per share, with such rights, preferences and limitations as may be set forth in resolutions adopted by~~ the ~~Board~~date ofwhen ~~Directors. On November 1, 2021,~~ the ~~Company~~financial ~~filed~~statements were aavailable ~~Certificate~~to ofbe ~~Designation designating 1~~issued,~~000,000~~ ~~shares~~to ofdetermine ~~Preferred Stock~~if asthey ~~Series~~must Abe ~~Convertible Preferred Stock (the “Series A”)~~reported. ~~Each~~Management ~~share~~ of the ~~Series A is convertible into three shares of the~~ Company’s ~~common~~determined ~~stock~~that atthere ~~the~~are ~~holder’s~~no ~~election,~~material ~~subject~~subsequent events to ~~a 4.99% beneficial ownership limitation which may~~ be ~~increased to~~disclosed ~~9.99%~~other ~~upon~~than 61those ~~days’~~described ~~notice~~below.

~~During the nine months ended September~~Subsequent ~~30,~~to ~~2025~~March ~~and 2024 there were no issuances of preferred stock. As of September 30~~31, 2025 ~~and December 31~~, ~~2024,~~ the Company ~~had~~issued ~~140~~300,~~000~~ 639 shares ofin ~~Series~~common Astock ~~Convertible~~for ~~Preferred~~cash ~~Stock~~proceeds ~~outstanding~~of $300,639.

~~Note 6 - Subsequent Events~~12

~~The~~Table Company has evaluated all events that occur after the balance sheet date through October 20, 2025, the date when the financial statements were available to be issued, to determine if they must be reported. Management of ~~the Company determined that there are no material subsequent events to be disclosed other than those described below.~~Contents

~~Subsequent to September 30, 2025,~~Item ~~the~~2. ~~Company~~Management’s ~~received~~Discussion ~~advances~~and Analysis of ~~$58,604~~Financial ~~from~~Condition ~~related parties~~ and ~~made~~Results ~~repayments~~ of ~~$150,000.~~Operations

12Cautionary Note Regarding Forward Looking Statements

~~Table~~This Report contains forward-looking statements within the meaning of ~~Contents~~the Private Securities Litigation Reform Act of 1995, including statements regarding our discussions and the anticipated terms of a potential reverse merger pursuant to which we would acquire an operating business, our business plan and our liquidity needs. All statements other than statements of historical facts contained in this Report, including statements regarding our future financial position, liquidity, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs.

~~Item~~The 2results anticipated by any or all of these forward-looking statements might not occur. ~~Management’s~~Important ~~Discussion~~factors, uncertainties and ~~Analysis~~risks ofthat may ~~Financial~~cause ~~Condition~~actual results to differ materially from these forward-looking statements include those described elsewhere in this Report and ~~Results~~in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 under “Item 1A. – Risk Factors.” We undertake no obligation to publicly update or revise any forward-looking statements, whether as the result of ~~Operations~~new information, future events or otherwise.

~~Cautionary~~Recent ~~Note Regarding Forward Looking Statements~~Developments

~~This~~Corporate ~~Report~~Name contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our discussions and the anticipated terms of a potential reverse merger pursuant to which we would acquire an operating business, our business plan and our liquidity needs. All statements other than statements of historical facts contained in this Report, including statements regarding our future financial position, liquidity, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs.Change

~~The~~On ~~results~~February ~~anticipated~~21, ~~by any or all of these forward-looking statements might not occur. Important factors~~2025, ~~uncertainties~~the ~~and~~Company ~~risks~~filed ~~that may~~a ~~cause~~Certificate ~~actual~~of ~~results~~Amendment to ~~differ~~its ~~materially~~Amended ~~from~~and ~~these~~Restated ~~forward-looking~~Certificate ~~statements~~of ~~include~~Formation ~~those~~with ~~described~~the ~~elsewhere in this Report~~Secretary ~~and~~of inState ~~our~~of ~~Annual~~Nevada ~~Report~~to onchange ~~Form 10-K for~~ the ~~fiscal~~Company’s ~~year~~corporate ~~ended~~name ~~December~~to ~~31, 2024 under~~ “~~Item~~BioScience ~~1A.~~Health –Innovations ~~Risk Factors~~Inc.” We, ~~undertake~~with noan ~~obligation~~effective date toof ~~publicly~~February ~~update~~21, or2025. ~~revise~~The ~~any~~name ~~forward-looking~~change ~~statements,~~was ~~whether~~approved asby the ~~result~~Company’s Board of ~~new~~Directors ~~information,~~on ~~future events~~February or21, ~~otherwise~~2025.

~~Recent Developments~~Overview

~~Corporate~~As ~~Name~~a ~~Change~~leadership team we are optimistic and excited about our opportunities to carve out very profitable positions in the marketplace through our patent-pending Methylene Blue products along with our additional specialty product offerings. The market opportunities we are targeting includes: Dementia and Alzheimer’s disease, ADHD and ADD, Long Covid, General Energy, Traumatic Brain Injury, Mild Cognitive Decline, GLP-1 Weight Loss, Sleep Improvement, Epilepsy and Seizure Reduction and Nasal Health and Allergy.

OnA trend ~~February~~that ~~21,~~we ~~2025,~~believe is very beneficial and encouraging is the ~~Company~~recent ~~filed~~growing ainterest ~~Certificate~~in mitochondria health and the role that mitochondria ofdysfunction ~~Amendment~~plays toin ~~its~~mental ~~Amended~~health and ~~Restated~~physical ~~Certificate~~health ofissues. ~~Formation~~Methylene ~~with~~Blue ~~the~~and ~~Secretary~~specialty ofnatural ~~State~~options ofhas ~~Nevada~~emerged toas ~~change~~valuable ~~the Company’s~~foundational ~~corporate~~health ~~name~~options toon ~~“BioScience~~these ~~Health~~fronts. ~~Innovations~~We ~~Inc.”,~~believe ~~with~~we anare ~~effective~~very ~~date~~well ofpositioned ~~February~~and ~~21,~~with ~~2025.~~adequate ~~The~~capital ~~name~~infusion ~~change~~we ~~was~~will ~~approved by~~be ~~the~~able ~~Company’s~~to ~~Board~~capitalize on ofmultiple ~~Directors~~market opportunities.

~~Change in Authorized Common Stock~~13

OnTable ~~September 10, 2025, the Company filed a Certificate~~ of Amendment to its Amended and Restated Certificate of Formation to Amendment the Article of Incorporation with the Secretary of State of Nevada to amend the authorized voting common shares from 75,000,000 to 250,000,000 with an effective date of September 10, 2025. The name change was approved by the Company’s Board of Directors.Contents

~~Common~~CRITICAL ACCOUNTING ~~Stock~~POLICIES ~~Reverse~~AND ~~Split (1:4)~~ESTIMATES

OnManagement’s discussion ~~September~~and ~~10,~~analysis ~~2025,~~and results of operations are based upon our accompanying financial statements for the ~~Company~~three ~~filed~~months aended ~~Certificate~~March of31, ~~Amendment~~2026, which have been prepared in conformity with U.S. generally accepted accounting principles, or U.S. GAAP, and which requires us to ~~its~~make ~~Amended~~estimates and ~~Restated~~assumptions ~~Certificate~~that affect the reported amounts of ~~Formation~~assets, ~~with~~liabilities, ~~the~~revenue ~~Secretary~~and expenses, and related disclosure of ~~State~~contingent assets and liabilities. Note 3. Summary of ~~Nevada~~Significant Accounting Policies, to ~~affect~~the afinancial ~~reverse~~statements ~~split~~included ofin ~~its~~Part ~~voting~~I, ~~common~~Item ~~stock~~1 of this Quarterly Report on Form 10-Q, describes the ~~basis~~significant ofaccounting ~~one~~policies ~~(1)~~and ~~Common~~methods ~~share~~used ~~for~~in ~~each~~the 4preparation ~~(four)~~of the ~~Common~~Company’s ~~shares~~financial ~~outstanding~~statements. ~~Fractional~~We ~~shares~~base ~~will~~our ~~not~~estimates beon ~~issued. Any~~historical ~~fractional~~experience ~~shares~~and ~~will~~on bevarious ~~rounded~~other ~~upward~~assumptions tothat ~~the~~we ~~next~~believe are ~~whole~~reasonable ~~share~~under the circumstances. ~~The~~These ~~reverse~~estimates ~~split~~are ~~was~~the ~~approved~~basis byfor our judgments about the ~~Company’s~~carrying ~~Board~~values of ~~Directors~~assets and liabilities, which in turn may impact our reported revenue and expenses. Our actual results could differ significantly from these estimates under different assumptions or conditions.

~~Overview~~Results Of Operations

AsTHREE aMONTHS ~~leadership~~ENDED ~~team~~MARCH we are optimistic and excited about our opportunities to carve out very profitable positions in the marketplace through our patent-pending Methylene Blue products along with our additional specialty product offerings. The market opportunities we are targeting includes: Dementia and Alzheimer’s disease31, ~~ADHD~~2026 ~~and~~COMPARED ~~ADD,~~TO ~~Long~~MARCH ~~Covid~~31, ~~General Energy, Traumatic Brain Injury, Mild Cognitive Decline, GLP-1 Weight Loss, Sleep Improvement, Epilepsy and Seizure Reduction and Nasal Health and Allergy.~~2025

~~A trend~~Our ~~that~~net weloss ~~believe~~for isthe ~~very~~three ~~beneficial~~months ~~and~~ended ~~encouraging~~March is31, 2026 was $229,907 compared to a net income of $426,798 during the ~~recent~~three ~~growing~~months ~~interest~~ended inMarch ~~mitochondria~~31, ~~health~~2025. The Company has generated revenue of $750,946 and $1,227,070 during the ~~role~~three ~~that~~months ~~mitochondria~~ended March 31, 2026 and 2025, respectively. This change is a result of adjustments in the Company’s sales ~~dysfunction~~channels. ~~plays~~The Company retained a new Amazon distributor to improve sales in ~~mental~~this ~~health~~area and ~~physical~~is ~~health~~transitioning ~~issues~~to a more targeted marketing strategy with a focus on specific key areas. ~~Methylene~~The ~~Blue~~Company ~~and~~had ~~specialty~~expected ~~natural~~a ~~options~~significant ~~has~~order ~~emerged~~from asa ~~valuable~~major ~~foundational~~Co-brand customer, but due to unforeseen ~~health~~events ~~options~~the onorder ~~these~~was ~~fronts~~rescheduled to the second quarter. WeExpenses ~~believe~~incurred wewere ~~are~~general ~~very~~administrative ~~well~~expenses ~~positioned~~of $625,809 and ~~with~~consulting expenses ~~adequate~~of ~~capital~~$89,694 ~~infusion~~during wethe ~~will~~three bemonths ~~able~~ended March 31, 2026, compared to ~~capitalize~~$433,561 and $35,786 during the three months ended March on31, ~~multiple~~2025. Consulting expenses increased as a result of the Company applying to move from the OTC (Over-the-Counter) market ~~opportunities~~to a senior exchange. In addition, wage expenses have increased along with an increase in accounting due to an upgrade in the accounting system. Management is still confident in reaching the projected year over year growth.

13LIQUIDITY AND CAPITAL RESOURCES

~~Table~~As of ~~Contents~~March 31, 2026, our total assets were $2,330,239, consisting of cash, accounts receivable, inventory, prepaid expenses, right-of-use assets, deposits, and intangible assets. The Company’s net working capital was $1,549,089 and management believes that its cash balance of $1,145,005 as of March 31, 2026 is sufficient to meet its obligations over the next year

~~CRITICAL~~Cash ~~ACCOUNTING~~Flows ~~POLICIES~~from ~~AND~~Operating ~~ESTIMATES~~Activities

~~Management’s discussion and analysis and~~We ~~results~~have ofgenerated ~~operations~~negative ~~are~~cash ~~based~~flows ~~upon~~from ~~our~~operating ~~accompanying~~activities. ~~financial~~For ~~statements for~~ the three ~~and nine~~ months ended ~~September~~March 3031, ~~2025~~2026, ~~which have~~net ~~been~~cash ~~prepared~~flows used in ~~conformity with U.S. generally accepted accounting principles, or U.S. GAAP, and which requires us to make estimates~~operating ~~and~~activities ~~assumptions~~was ~~that affect the reported amounts of assets~~$552, ~~liabilities~~107, ~~revenue~~consisting ~~and expenses, and related disclosure~~ of ~~contingent~~our ~~assets and~~net ~~liabilities.~~loss ~~Note 3. Summary~~ of ~~Significant Accounting Policies~~$229,907 toplus ~~the~~changes ~~financial statements included~~ in ~~Part~~operating I,activities ~~Item 1~~ of ~~this Quarterly Report on Form 10-Q~~$322,200. ~~describes~~For the ~~significant~~three ~~accounting policies and methods used in the preparation of the Company’s financial~~months ~~statements.~~ended WeMarch ~~base~~31, ~~our~~2025, ~~estimates~~net oncash ~~historical~~flows ~~experience~~providing ~~and~~in onoperating ~~various~~activities ~~other~~was ~~assumptions~~$328,309, ~~that~~consisting weof ~~believe are reasonable under the circumstances. These estimates are the basis for~~ our ~~judgments~~net ~~about~~income ~~the carrying values~~ of ~~assets and liabilities~~$426,798 ~~which in turn may impact our reported~~offset ~~revenue~~by ~~and~~changes ~~expenses.~~in ~~Our~~operating ~~actual~~activities ~~results~~of ~~could differ significantly from these estimates under different assumptions or conditions~~$98,489.

~~Results~~Cash OfFlows ~~Operations~~from Investing Activities

~~THREE~~For the ~~MONTHS~~three ~~ENDED~~months ~~SEPTEMBER~~ended 30March 31, ~~2025~~2026, ~~COMPARED~~we had no cash flows used in or provided by investing activities. For the three months ended March TO31, ~~SEPTEMBER~~2025, we had net cash used in investing activities of $30,000 ~~2024~~in connection with the purchase of intangible assets.

~~Our net loss for the three months ended~~Cash ~~September~~Flows 30, 2025 was $8,782 compared to net income of $56,202 during the three months ended September 30, 2024. The Company has generated revenue of $1,131,427 and $572,973 during the three months ended September 30, 2025 and 2024, respectively. The increase in revenue over time is due to Company growth and increased sales and marketing efforts, which also explains the change from ~~period to~~Financing period. Expenses incurred were general administrative expenses of $576,656 and consulting expenses of $130,357 during the three months ended September 30, 2025, compared to $345,288 and $23,250 during the three months ended September 30, 2024 and was due to the overall growth of the Company and its operations in conjunction with its increase in revenues.Activities

~~NINE~~For the ~~MONTHS~~three ~~ENDED~~months ~~SEPTEMBER~~ended 30March 31, 2026, net cash flows provided by financing activities was $1,035,187, consisting of $748,120 in advances from related parties and $437,067 of cash acquired for selling common stock, offset by repayments to related parties of $150,000. For the three months ended March 31, 2025, ~~COMPARED~~net cash flows provided by financing activities was $67,516, consisting of advances from related TOparties ~~SEPTEMBER~~of 30$589,516 ~~2024~~offset by repayments to related parties of $522,000.

Our net income for the nine months ended September 30, 2025 was $875,720, compared to a net income $77,043 during the nine months ended September 30, 2024. The Company has generated revenue of $4,115,960 and $1,234,744 during the nine months ended September 30, 2025 and 2024, respectively. The increase in net income was due to an increase in sales and marketing efforts. Operating expenses were $1,793,134 during the nine months ended September 30, 2025, compared to $892,836 during the nine months ended September 30, 2024. The increase in operating expenses was due to overall growth of the Company and its operations in conjunction with our increase in revenues.14

~~LIQUIDITY~~Table ~~AND~~of ~~CAPITAL RESOURCES~~Contents

~~As of September 30, 2025, our total assets were~~PLAN ~~$2,067,100~~OF ~~consisting~~OPERATION ofAND ~~cash, accounts receivable, inventory, prepaid expenses, and intangible assets.~~FUNDING

~~Cash~~Currently, the ~~Flows~~Company ~~from~~is ~~Operating~~in ~~Activities~~the process of offering a private placement to accredited investors to raise up to $1,000,000. Once the private placement is complete the Company will begin the process of preparing and filing Form 1-A with the SEC.

WeThe BioScience ~~have~~Health ~~generated~~Innovations’ ~~positive~~management ~~cash~~team ~~flows~~plans ~~from~~to ~~operating activities.~~focus ~~For~~on ~~the~~gaining ~~nine~~traction ~~months~~for ~~ended~~its ~~September~~mental ~~30,~~health ~~2025~~and general wellness products. Best 365 Labs, ~~net~~Inc ~~cash~~has ~~flows~~filed ~~provided~~for ina ~~operating~~provisional ~~activities~~patent ~~was~~on ~~$272~~its mental wellness,~~874,~~ ~~consisting~~natural ~~of our~~products ~~net~~which ~~income~~is ofan ~~$875,720~~additional ~~offset~~reason bywe ~~changes~~plan to infocus ~~operating~~and ~~activities~~grow this sector of ~~$602,846~~the products. ~~For~~With the ~~nine~~Global ~~months~~Mental ~~ended~~Health ~~September~~Marketplace ~~30,~~currently ~~2024,~~valued ~~net~~at ~~cash~~$383.31 billion annually ~~flows~~and ~~used~~with in41 ~~operating~~million ~~activities~~people ~~was~~holding ~~$73,493,~~a ~~consisting~~prescription offor ~~our~~Adderall ~~net~~that ~~income~~the ofmarket ~~$77,043~~conditions ~~offset~~are byidea ~~changes~~for inus ~~operating~~to ~~activities~~offer ofour ~~$3,550~~natural substitute product options (which are also unique).

~~Cash~~As a ~~Flows~~leadership ~~from~~team ~~Investing~~we ~~Activities~~are optimistic and excited about our opportunities to carve out very profitable positions in these potential marketplaces, through our patent-pending Methylene Blue products along with our additional specialty product offerings. The market opportunities we are targeting include:

~~For the nine months ended September 30, 2025,~~Management weDiscussion ~~had~~and net cash used in investing activities of $46,064 in connection with the purchase of intangible assets. For the nine months ended September 30, 2024, we had net cash used in investing activities of $7,037 in connection with the purchase of intangible assets.Analysis

~~Cash~~BioScience Health ~~Flows~~Innovations ~~from~~Inc., ~~Financing~~through ~~Activities~~its wholly owned subsidiary Best 365 Labs, Inc., is a biotech and nutraceutical company focused on cellular health optimization, testosterone replacement therapy, and advanced nutrient delivery systems. The Company’s proprietary MODS Max (Mineral Oxide Delivery System) process dramatically enhances the bioavailability of peptides, vitamins, amino acids, and other bioactive compounds through a patent-pending mechanism that uses mineral oxychlorides to generate microdose reactive oxygen species (ROS), transiently opening tight junctions in mucosal membranes.

~~For~~The Company ~~the~~operates ~~nine~~from ~~months~~its ~~ended~~headquarters ~~September~~in 30Bluffdale, ~~2025~~Utah, ~~net~~ ~~cash~~manufactures ~~flows~~non-prescription ~~provided~~products bythrough ~~financing~~CGMP-compliant ~~activities was $250~~facilities,~~096,~~ and ~~consisting~~maintains ofseveral ~~$2,422,096~~503A inpharmacy ~~advances~~relationships ~~from~~for ~~related~~the ~~parties~~production ~~and~~of ~~offset~~prescription-related ~~by repayments~~products. toBHIC ~~related~~is ~~parties~~actively ofworking ~~$2,172,000.~~toward establishing ~~For~~its ~~the~~own ~~nine~~503A ~~months~~compounding ~~ended~~facility. ~~September~~The ~~30,~~Company ~~2024,~~sells ~~net~~products ~~cash~~through ~~flows~~five ~~provided~~established byrevenue ~~financing~~channels: ~~activities~~direct-to-consumer ~~was $247~~(website),~~526,~~ ~~consisting~~TPrime365 ~~of,~~subscription ~~advances from related parties of $692~~program,~~746,~~ ~~and $300~~Amazon,~~000~~ ofB2B ~~cash~~wholesale ~~acquired for selling common stock~~(TWC), ~~offset by~~and ~~repayments~~strategic topartnerships ~~related~~(including ~~parties~~the ofDwayne ~~$745,220~~Deal).

14Three Core Value Drivers

~~Table~~1. Testosterone/Hormonal ofOptimization ~~Contents~~(NHTO)

~~PLAN OF~~a) ~~OPERATION~~Flagship ~~AND~~product: ~~FUNDING~~TPrime365 (MODS Max Gold) — a 4-in-1 sublingual testosterone optimizer containing Enclomiphene (25mg), Spermidine (10mg), Boron (10mg), and Vitamin C (10mg)

~~The BioScience~~b) ~~Health~~Non-injectable ~~Innovations’~~sublingual ~~management~~delivery ~~team~~via ~~plans~~MODS toMax focus on gaining traction for its mental health and general wellness products. Best 365 Labs, Inc has filed for a provisional patent on its mental wellness, natural products which is an additional reason we plan to focus and grow this sector of the products. With the Global Mental Health Marketplace currently valued at $383.31 billion annually and with 41 million people holding a prescription for Adderall that the market conditions are idea for us to offer our natural substitute product options (which are also unique).process

~~As a~~c) ~~leadership~~Up ~~team we are optimistic and excited about our opportunities~~ to ~~carve~~600% ~~out~~testosterone ~~very~~increase ~~profitable~~documented ~~positions~~ in ~~these~~24 ~~potential marketplaces, through our patent-pending Methylene Blue products along with our additional specialty product offerings. The market opportunities we are targeting include:~~weeks

~~Management’s~~d) ~~Discussion~~5,000+ ~~and~~patient-uses ~~Analysis~~with ofzero ~~Financial~~serious ~~Condition and~~adverse ~~Results of Operations~~events

~~For~~e) ~~the~~Licensed ~~Quarterly~~physician ~~Period~~consultation ~~Ended~~included ~~September~~via ~~30,~~HappyMD ~~2025~~partnership

~~During~~f) ~~the~~TRT ~~third~~Market: ~~quarter of 2025, BioScience Health Innovations Inc~~$2.1B ~~continued its transformation and growth initiatives to position the company as a leading innovator in therapeutic delivery~~(2026), ~~health~~ ~~optimization,~~projected ~~and specialty pharmacy markets~~$2.6B ~~Key~~by ~~updates and business developments for the period include:~~2031

~~Corporate Rebranding and Structure~~15

●Table Weof have changed our corporate name from Nowtransit to BioScience Health Innovations Inc. and our trading symbol from “NT” to “BHIC”. This rebranding reflects our clear commitment and strategic focus on advanced health science innovations and our proprietary delivery systems.Contents

~~● We have prepaid for 1 year of comprehensive Director and Officers (D&O) insurance including cyber security coverage~~2. NAD+ ~~This~~/ ~~strategic~~Cellular investment provides essential protection for our leadership team and the company against potential claims arising from our decisions and actions as we transition to a public company operating under heightened regulatory scrutiny and increased shareholder oversight. The integrated cyber security component of our D&O coverage addresses the growing intersection of cyber risks and executive liability, providing protection against claims that may arise from cyber incidents, data breaches, or alleged failures in cybersecurity governance.Health

~~Intellectual Property~~a) ~~and~~Patent-pending ~~Brand~~NAD+ ~~Development~~restoration approach achieving 60–90% bioavailability vs. 10–20% conventional oral

●b) WeProduct ~~have~~lines: ~~secured~~NAD+PQQ ~~the~~Boost, ~~domain~~UCOS ~~name~~(Ultimate ~~www.MODSMAX.com~~Cellular toOptimization ~~establish a dedicated digital presence for our flagship technology platform~~System), ~~enhancing our direct-to-consumer marketing capabilities and brand recognition.~~Triple

●c) ~~The~~Power ~~company~~Methylene ~~has~~Blue, ~~applied~~Renew365, ~~for~~MitoBoost aUltra, ~~MODS~~NeuroPro ~~Max~~Plus, ~~trademark~~NeuroPro toMemory, ~~protect~~Brain ~~our~~Fog ~~proprietary~~Support, ~~Mineral~~ADHD ~~Oxide Delivery System brand~~365, ~~reinforcing our intellectual property portfolio and competitive positioning in the advanced delivery systems market.~~Metabolism+

●d) ~~Our~~Standard ~~Best~~Packs: ~~365~~Chronic ~~Labs~~Fatigue ~~trademark~~Fighter, ~~has~~Concussion ~~been~~Recovery ~~published~~Support, ~~further~~Focus ~~strengthening~~& ~~our~~Attention, ~~portfolio~~Longevity of& ~~protected~~Vitality, ~~brand~~Memory ~~assets~~& ~~and~~Longevity, ~~establishing~~Mood ~~clear~~Support, ~~market~~Premium ~~differentiation.~~Energy, Women’s Health

●e) WeImmune ~~have~~health ~~six~~products: ~~patents pending covering our core delivery technologies, including our patent~~Be-~~pending~~OnGuard ~~MODS~~Nasal ~~Max (Mineral Oxide Delivery System) platform~~Spray, ~~which~~Mouth creates 5-10 years of market exclusivity. These patents protect our mineral oxychloride technology that generates controlled reactive oxygen species for enhanced bioavailability and antimicrobial activity.Spray

●f) ~~Our~~Comparables: ~~patent-pending~~NAGE ~~enclomiphene~~(ChromaDex) ~~delivery~~at ~~system~~$390–$812M ~~demonstrates~~market ~~breakthrough~~cap ~~clinical validation~~ with ~~average~~~90 testosterone improvements of 56.3% across diverse age groups, with patent protection extending through 2031-2033. Recent clinical outcomes show remarkable results including a 30-year-old patient achieving testosterone levels increasing from 566 to 1,212 ng/dL and a new 32-year-old physician assistant patient achieving dramatic improvement from 120 to 917 ng/dL after just 3 weeks.patents

15g) NAD+ Market: $5.6B (2025), projected $11.7B by 2030

~~Table~~3. Platform ofLicensing ~~Contents~~/ Peptide Delivery

●a) ~~The~~MODS ~~company’s~~Max ~~patent-pending~~enables ~~methylene~~oral ~~blue~~delivery ~~stabilization~~of ~~technology~~peptides ispreviously ~~being~~requiring ~~put~~injection ~~through~~(BPC-157, ~~additional~~GHK ~~stability~~Cu, ~~studies~~TB-500, ~~for~~Thymosin ~~potency~~Alpha-1, ~~retention\~~AOD-9604, ~~compared to standard formulations that have been reported to lose 50% potency within 3 days~~CJC-1295, ~~representing~~and ~~a significant technological advancement.~~others)

●b) ~~Our~~503A ~~patent-pending~~pharmacy ~~sublingual~~partner ~~delivery~~pathway ~~technology shows potential for improved bioavailability compared to standard capsules~~ and ~~could qualify for FDA~~ 505(b)(2) ~~pathway~~regulatory ~~classification as a “new dosage form~~strategy,” ~~which~~with ~~could~~BHIC ~~provide~~working ~~regulatory~~toward ~~advantages~~establishing ~~and~~its ~~competitive~~own ~~differentiation.~~503A ~~The company has started additional stability studies to further validate the technology platform and support regulatory submissions.~~facility

~~MODS Max~~c) ~~Technology~~30+ ~~Platform~~proprietary ~~and~~MODS ~~Market~~Max ~~Opportunity~~formulations in pipeline

~~Technology Mechanisms~~d) FDA Peptide Reclassification Catalyst (February 27, 2026): On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced on The Joe Rogan Experience that approximately 14 of the 19 peptides placed on the FDA’s Category 2 restricted list in late 2023 will be moved back to Category 1. As of April 2026, the FDA is expected to formally implement this reclassification imminently, per Reuters and ~~Advantages~~the New York Times. Category 1 status would allow licensed 503A compounding pharmacies to legally prepare these peptides under valid physician prescriptions. This directly expands BHIC’s addressable market through its 503A compounding facility and MODS Max oral delivery platform.

~~MODS~~4. ~~Max~~Peptides ~~(Mineral~~Expected ~~Oxide~~to ~~Delivery~~Return ~~System) represents our flagship patent-pending technology that leverages mineral oxychloride compounds~~ to ~~generate~~ ~~microdose~~Category ~~amounts of reactive oxygen species (ROS) such as hydrogen peroxide and hydroxyl radicals. This innovative approach:~~1

●a) ~~Enhances~~BPC-157 ~~Absorption:~~— ~~Achieves~~Tissue ~~over 10x increased permeability by gently and temporarily opening biological barriers like sublingual mucosa~~repair, ~~enabling~~gut ~~superior passive transport of nutrients, peptides, and active compounds.~~health

●b) ~~Broad~~Thymosin Alpha-~~Spectrum~~1 ~~Antimicrobial~~(Tα1) ~~Activity:~~— ~~The~~Immune ~~oxidative environment inactivates key microbial enzymes and disrupts structural integrity of pathogens, reducing fungal and bacterial loads while providing natural preservative effects.~~modulation

●c) ~~Universal~~AOD-9604 ~~Compatibility:~~— ~~Works~~Fat effectively with vitamins, amino acids, minerals, plant extracts, and advanced peptide actives without requiring specialized reformulation, making it suitable for daily use in beverages, oral shots, or sublingual forms.metabolism

●d) ~~Superior Stability: Achieves 18~~GHK-~~month~~Cu ~~shelf~~— ~~stability~~Skin ~~without refrigeration requirements while maintaining antimicrobial activity~~regeneration, ~~addressing~~wound ~~critical supply chain challenges.~~healing

~~Market Positioning~~e) ~~and~~CJC-1295 ~~Opportunities~~— Growth hormone signaling

~~MODS Max~~f) ~~addresses~~Ipamorelin ~~multiple~~— ~~high-growth~~Growth ~~healthcare~~hormone ~~segments with substantial total addressable market opportunities:~~stimulation

●g) ~~Oral GLP~~TB-1500 ~~Agonists~~/ ~~Market:~~Thymosin ~~$156.7B~~Beta-4 Fragment (~~2030-2033~~LKKTETQ) -— ~~MODS~~Tissue ~~Max enables sublingual delivery and improved patient compliance~~regeneration

●h) ~~Testosterone~~Selank ~~Replacement~~Acetate ~~Therapy:~~(TP-7) ~~$2.79B~~— -Cognitive ~~Non-injectable~~enhancement, ~~fertility~~anti-~~preserving alternatives~~anxiety

●i) ~~Compounding~~Semax ~~Pharmacies:~~— ~~$23B - New specialty formulations with higher margins~~Neuroprotection

●j) ~~Transmucosal~~KPV ~~Drug~~— ~~Delivery: $129.46B~~ Anti- ~~Platform for peptides, hormones, and nutraceuticals~~inflammatory

~~● Sleep Aid Supplements: $12.9B (2034~~k) MOTS-C ~~Enhanced~~— ~~peptide~~Metabolic ~~delivery for dual-action formulations~~regulation

~~● Longevity Market: $63.0B (2035~~l) -Melanotan ~~Bioavailable~~II ~~telomerase~~— ~~activators~~Skin ~~and cellular renewal compounds~~pigmentation

~~Clinical Validation~~m) ~~and~~PEG-MGF ~~Early~~— ~~Adopter~~Muscle ~~Success~~repair

~~Our MODS~~n) ~~Max~~DSIP ~~technology~~(Emideltide) ~~has~~— ~~demonstrated~~Sleep ~~exceptional clinical outcomes and market validation through strategic partnerships and early adopters including:~~regulation

~~● 10X Health: Methylene Blue Drops combining methylene blue, mineral oxide, and black pepper extract for enhanced mitochondrial function and cognitive support~~16

●Table ~~DaVinci~~of ~~Medical: Pharmaceutical-grade methylene blue liquid energy formulations designed for use with red light therapy~~Contents

●5. Why ~~Best~~This ~~365~~Is ~~Labs~~Material ~~Product Line: Including RestoraSleep (longevity formula with clinical-grade epithalon), Toolbox Stack combinations~~ for ~~mitochondrial support, and various specialized therapeutic formulations~~BHIC

16a) BHIC’s MODS Max process converts injection-only peptides to oral delivery — the reclassification creates immediate commercial opportunity for oral peptide products that were previously illegal to compound

~~Table~~b) ofBHIC’s ~~Contents~~established 503A pharmacy relationships position the Company to compound these peptides immediately upon reclassification, and BHIC’s planned proprietary 503A facility will provide additional in-house compounding capability

~~Strategic Partnerships~~c) &BHIC’s ~~Expansion~~GLOW Recover Peptide product (containing GHK-Cu, BPC-157, and TB-500) is directly aligned with compounds expected to return to Category 1

●d) We30+ ~~are actively pursuing strategic partnerships and market opportunities aligned with~~ MODS Max, ~~our~~formulations ~~patent-pending Mineral Oxide Delivery System. MODS Max has attracted strong interest from potential partners~~ in ~~both~~pipeline ~~the~~can ~~supplement/pharmaceutical~~target ~~sector~~these ~~and~~newly ~~clinical~~accessible ~~compounding pharmacy channels, signaling validation of our technology platform.~~compounds

~~● Our technology creates exceptional revenue opportunities for 503A compounding pharmacies, with projected market growth from $4.47B in 2024 to $8.08B by 2034 (6.1% CAGR~~e) ~~and~~First-mover ~~503B~~advantage: ~~pharmacies~~BHIC’s ~~growing~~oral ~~from~~delivery ~~$1.25B~~capability toprovides ~~$2.42B~~differentiation (7vs.6% ~~CAGR). Conservative financial projections demonstrate that a 50~~injection-~~location~~only ~~pharmacy chain could generate $2.4 million annual revenue with $840,000 gross profit using our formulations.~~competitors

●f) ToThe ~~further~~reclassification ~~our~~expands ~~international growth, we have begun~~ the ~~needed~~total ~~steps~~addressable ~~for~~peptide ~~registration~~wellness ofand ~~key~~therapeutic ~~products in Dubai~~market, ~~opening~~which ~~opportunities~~intersects ~~for~~with ~~entry into~~ the ~~Middle~~GLP-1 ~~Eastern~~market ~~health~~projected ~~and~~at ~~wellness~~$130B ~~markets~~by ~~and new distribution and licensing partnerships.~~2030

~~Operational Execution~~g) &Important ~~Market~~caveat: ~~Positioning~~Category 1 reclassification does not constitute FDA approval; peptides remain o-label therapeutics requiring physician prescription and supervision; formal rulemaking by the FDA has not yet been published as of April 2026

●h) WeGLOW ~~continued~~Recover toPeptide: ~~focus~~Contains on150mg ~~capital~~GHK-~~efficient~~Cu, ~~high-margin~~10mg ~~growth through our direct~~BPC-~~to-consumer channels~~157, ~~supported~~10mg ~~by web subscriptions and targeted online marketing campaigns, now enhanced by our dedicated MODS Max digital platform.~~TB-500

●i) ~~The~~Comparable ~~company~~transactions: ~~has~~Merck ~~retained~~paid ~~and~~$493M isfor ~~working~~Cyprumed on(oral ~~launching~~peptide andelivery); ~~upgraded~~L’Catterton ~~best365labs.com~~acquired ~~retail~~Thorne ~~and wholesale website, targeting an August 2025 launch with integrated NetSuite platform~~ for accounting. This enhanced e-commerce infrastructure will streamline our operations, improve customer experience, and provide robust financial management capabilities to support our expanding product portfolio and wholesale distribution channels.$680M

●j) ~~Ongoing discussions are also underway with pharmacy groups and specialty clinical partners to expand access to our MODS Max platform via co~~GLP-~~branding,~~1 ~~licensing,~~Market: ~~and~~$130B ~~modular~~by ~~white-label arrangements.~~203

●6. Shipping ~~Our team is also evaluating additional global registration~~ and ~~commercialization~~Fulfillment ~~pathways to advance commercial readiness for MODS Max and proprietary product lines.~~Operations

~~Financial~~Best ~~Performance~~365 Labs fulfills substantially all customer and ~~Growth~~wholesale ~~Metrics~~orders directly from its Bluffdale, Utah facility, where the Company maintains in-house control over inventory management, order processing, packaging, and outbound logistics. The only exception is compounded preparations produced through the Company’s 503A pharmacy partners, which are dispensed and shipped directly from those licensed partner pharmacies in accordance with applicable state and federal regulations governing patient-specific compounded products. All other Best 365 Labs products ship from the Bluffdale location. By operating fulfillment internally rather than outsourcing to third-party logistics providers, the Company is able to enforce consistent quality assurance standards, protect product integrity through proper handling and storage conditions, and maintain real-time visibility into inventory levels and shipment status. Orders are typically processed and shipped within one to two business days of receipt, with tracking information provided to customers upon dispatch. The Bluffdale facility ships nationwide via established carrier partnerships, and the Company continually evaluates carrier performance, packaging materials, and routing to optimize transit times and minimize damage in transit. Management believes that direct-from-facility fulfillment is a meaningful component of the customer experience and a competitive differentiator. Taking pride in every order shipped, the Company’s fulfillment team is committed to ensuring that each consumer and wholesale partner receives accurate, properly packaged, and timely shipments, reinforcing brand trust and supporting customer retention. The Company expects to continue investing in fulfillment infrastructure, staffing, and process improvements at the Bluffdale location as order volume scales.

~~During Q2 2025, the company demonstrated strong operational performance with:~~17

●Table ~~Revenue Growth: Continued expansion~~ of ~~our direct-to-consumer channels with enhanced MODS Max-powered product lines~~Contents

~~● Margin Optimization~~Strategic Acquisitions: ~~Achieving 65%+ margins via website subscriptions and product packs while leveraging automation and targeted digital marketing campaigns~~

●We will ~~Wholesale~~evaluate ~~Expansion:~~strategic ~~Establishing~~partnerships ~~baseline~~or ~~revenue~~acquisitions ~~floor~~that ofalign ~~$250/month from over 2,100 clinics~~ with ~~telehealth~~our ~~upsells~~vision ~~driving~~and ~~additional~~provide ~~revenue~~value ~~growth~~to stakeholders.

●Leadership & ~~Strategic~~Governance Validation: Co-branded product offerings with DaVinci Medical/10X Health and The Wellness Company (TWC) leverage their established audiences and protocols to enhance mitochondrial health education and market reachEnhancements

~~Risk~~ Management is ~~and~~actively ~~Regulatory~~working ~~Compliance~~to strengthen leadership by adding two independent directors prior to a Nasdaq uplist.

~~The~~OFF-BALANCE ~~company~~SHEET ~~maintains robust risk management practices while pursuing growth opportunities:~~ARRANGEMENTS

●We have ~~Regulatory~~no ~~Alignment:~~off-balance ~~Our~~sheet ~~liquid~~arrangements ~~mineral~~that ~~delivery~~have ~~solutions~~or ~~provide~~are ~~differentiated~~reasonably ~~dosage~~likely ~~forms~~to ~~that~~have ~~adhere~~a tocurrent ~~FDA~~or ~~requirements~~future ~~for~~effect ~~compounded~~on ~~drugs~~our ~~under~~financial ~~Section~~condition, changes ~~503A~~in financial condition, revenues or expenses, results of ~~the~~operations, ~~FD&C~~liquidity, ~~Act~~capital expenditures or capital resources.

~~● Patent Protection: Six pending patents create 5-10 years of market exclusivity for our oral delivery and catalytic blend technologies~~18

17Table of Contents

~~Table~~Item 3. ofQuantitative ~~Contents~~and Qualitative Disclosures About Market Risk

● Safety Protocols: MODS Max technology utilizes precisely controlled, microdose ROS generation that cooperates with the body’s natural antioxidant defenses, avoiding the destructive effects of uncontrolled oxidative stressNot required.

●Item 4. ~~Quality~~Controls ~~Assurance: Our formulations maintain stability~~ and ~~potency through advanced stabilization technologies and rigorous quality control processes~~Procedures

~~Outlook~~Disclosure Controls and Procedures

~~Management~~As ~~remains~~of ~~committed~~March to31, ~~innovation-led~~2026 ~~growth~~(the “Evaluation Date”), ~~capital~~the ~~structure~~Company’s ~~optimization~~management evaluated, ~~and~~with ~~regulatory~~participation ~~progress.~~of ~~These~~its ~~actions~~principal executive ~~are~~officer, ~~designed~~the toeffectiveness ~~position BioScience~~of ~~Health~~the ~~Innovations~~Company’s ~~for~~disclosure ~~sustainable~~controls ~~long-term~~and ~~expansion~~procedures, as defined in ~~both~~Rules US13a-15 ~~and~~of ~~global~~the ~~markets~~Securities Exchange Act of 1934, ~~while~~as ~~advancing~~amended ~~our~~(the ~~mission~~“Exchange toAct”). ~~deliver~~Based on that evaluation, the Company’s principal executive ~~next-generation~~officer ~~therapies~~concluded that the Company’s disclosure controls and ~~high-value~~procedures ~~partnership~~were ~~opportunities~~ineffective ~~powered~~as byof ~~MODS~~March ~~Max~~31, ~~technology~~2026.

Management assessed the effectiveness of its internal control over financial reporting as of the Evaluation Date based on criteria for effective internal control over financial reporting described in Internal Control—Integrated Framework issued in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission. The material weaknesses identified during management’s assessment were (i) ~~strengthening~~a lack of ~~our~~sufficient ~~intellectual~~internal ~~property~~accounting ~~portfolio~~resources; ~~through~~(ii) ~~multiple~~a ~~patent~~lack ~~applications~~of segregation of duties to ensure adequate review of financial statement preparation, ~~trademark~~(iii) ~~protections~~lack of an independent board of directors or audit committee, and ~~domain~~(iv) ~~acquisition, combined~~lack ~~with~~of written documentation of our ~~enhanced~~internal control ~~digital~~policies ~~infrastructure,~~and ~~integrated~~procedures. ~~accounting~~In ~~systems~~light of these material weaknesses, ~~and~~management ~~comprehensive~~has ~~executive~~concluded ~~liability~~that ~~insurance~~we ~~coverage,~~did not maintain effective internal ~~creates~~control ~~significant~~over ~~competitive~~financial ~~moats~~reporting ~~and~~at ~~positions~~the usEvaluation Date. We plan to rectify these weaknesses by establishing written policies and procedures for ~~enhanced~~our ~~brand~~internal ~~protection,~~control ~~premium~~of ~~pricing~~financial ~~capabilities,~~reporting and ~~accelerated~~hiring ~~market~~additional accounting personnel at such time as we raise sufficient capital ~~expansion~~to ~~across~~do ~~our~~so. ~~target~~There ~~therapeutic~~were ~~areas~~no changes in controls during the quarter ended March 31, 2026.

Our proactive approach to corporate governance and executive protection through comprehensive D&O insurance demonstrates our commitment to best practices as we prepare for Nasdaq uplisting and operate under the heightened standards expected of public companies.19

~~With MODS~~Table ~~Max~~of addressing multiple billion-dollar healthcare markets and demonstrating exceptional clinical validation across diverse patient populations, we are well-positioned to capture significant market share while delivering transformative health outcomes. The technology’s versatility as a universal delivery platform enables endless product innovation opportunities while creating sustainable competitive advantages through patent protection and regulatory positioning.Contents

ByPART ~~merging advanced mineral oxide delivery science with proven clinical outcomes, BioScience Health Innovations is positioned as a disruptive force in the therapeutic delivery marketplace~~II. ~~This~~OTHER comprehensive strategy addresses regulatory challenges, offers patients superior alternatives to traditional therapies, and drives sustained growth through strategic partnerships and commercialization efforts across multiple high-growth healthcare segments.INFORMATION

18Item 1. Legal Proceedings

~~Table~~Management is not aware of ~~Contents~~any legal proceedings contemplated by any governmental authority or any other party involving us or our properties. As of the date of this Quarterly Report, no director, officer or affiliate is (i) a party adverse to us in any legal proceeding, or (ii) has an adverse interest to us in any legal proceedings. Management is not aware of any other legal proceedings pending or that have been threatened against us or our properties.

~~OFF-BALANCE~~Item ~~SHEET~~1A. ~~ARRANGEMENTS~~Cybersecurity

WeTo ~~have~~date, nothe ~~off-balance~~Company ~~sheet~~has ~~arrangements~~not ~~that~~identified any cybersecurity incidents which have materially affected, or are reasonably likely to ~~have~~materially affect, athe ~~current~~Company’s orbusiness ~~future~~strategy, ~~effect~~results onof ~~our~~operations or financial condition,. The Company has not implemented any ~~changes~~specific inpolicies ~~financial~~with ~~condition,~~respect ~~revenues~~to ormonitoring ~~expenses~~and managing cybersecurity threats. Moreover, ~~results~~the Company is aware of ~~operations,~~the ~~liquidity,~~evolution ~~capital~~of ~~expenditures~~cybersecurity risks orand ~~capital~~is ~~resources~~taking proactive steps by keeping up to date our information systems and educating our personnel about these risks.

~~Going~~The ~~Concern~~Company recognizes the importance of developing, implementing, and maintaining cybersecurity measures to safeguard its information systems and protect the confidentiality, integrity, and availability of the data. The Company will be looking to adopt cybersecurity processes, technologies and controls to aid in its efforts to assess, prevent, identify and manage such risks.

~~Our~~Item business is subject to risks inherent in marketing products in a competitive market as we continue to sell clinically-tested, affordably priced products to naturally battle the onslaught of bacteria and viruses through online sales and in various other distribution channels2. ~~Presently,~~ ~~the~~Unregistered ~~Company~~Sales isOf ~~marketing~~Equity BeSecurities ~~On-Guard Mouth Spray, Be On-Guard Nasal Spray, EZ, Safer Surface Cleaner, Be On-Guard Brain Fog Support~~ and ~~ADHD~~Use ~~365~~Of ~~maximum strength brain support, while also having limited capital resources and expecting possible cost overruns due to price and cost increases in services and products.~~Proceeds

AsDuring ~~reflected in~~ the ~~condensed~~three ~~consolidated financial statements, the Company has generated revenues resulting in a net income during the nine~~ months ended ~~September~~March 3031, ~~2025 resulting in accumulated earnings of $534~~2026,~~637 and is showing total assets in excess of total liabilities as of September 30, 2025. However, in the~~ ~~past~~ the Company ~~has~~issued ~~reported~~437,067 ~~losses~~shares ~~and cash used~~ in ~~operating~~common ~~activities,~~stock ~~and~~for ~~has~~cash ~~relied on advances from related parties and~~ proceeds ~~from~~ ~~the sale~~ of ~~stock~~$437, ~~therefore has not yet developed a proven track record of profitability~~067. ~~These factors raise substantial doubt about the Company’s ability to continue as a going concern.~~

~~The Company is engaged in full-scale operations~~Item ~~as a distributor and generates revenue; however, the Company’s cash position may not be sufficient to support the Company’s daily operations long-term~~3. ~~While~~Defaults ~~the~~Upon ~~Company~~Senior believes in the viability of its strategy to commence operations and generate sufficient revenue and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate sufficient revenue.Securities

~~Item~~Not 3applicable. ~~Quantitative and Qualitative Disclosures About Market Risk~~

~~Not~~Item ~~required~~4. Mine Safety Disclosures

~~Item~~Not 4applicable. ~~Controls and Procedures~~

~~Disclosure~~Item ~~Controls~~5. ~~and~~Other ~~Procedures~~Information

~~As of September 30, 2025 (the “Evaluation~~Not Date”), the Company’s management evaluated, with participation of its principal executive officer, the effectiveness of the Company’s disclosure controls and procedures, as defined in Rules 13a-15 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)applicable. ~~Based on that evaluation, the Company’s principal executive officer concluded that the Company’s disclosure controls and procedures were ineffective as of September 30, 2025.~~

19Table of Contents

~~Table~~Item 6. ~~of Contents~~Exhibits

PART II. OTHER INFORMATION

Exhibit #	Exhibit Description	Incorporated By Reference			Filed or Furnished Herewith
		Form	Date	Number
3.1(a)	Articles of Incorporation	S-1	11/4/2019	3.1

3.1(b)	Amendment to Articles of Incorporation	10-K	11/26/2021	3.1B

3.2	Bylaws	S-1	11/4/2019	3.2

10.1	Stock purchase agreement dated August 29, 2022*	10-Q	08/11/2023	10.1

10.2	Stock purchase Agreement dated October 19, 2022*	10-Q	08/11/2023	10.2

10.3	Stock purchase Agreement dated December 20, 2022	10-Q	08/11/2023	10.3

31.1	Certification of Principal Executive Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a)				Filed

31.2	Certification of Principal Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a)				Filed

32.1	Certification of Principal Executive Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002				Furnished**

32.2	Certification of Principal Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002				Furnished**

101	Inline Interactive data files pursuant to Rule 405 of Regulation S-T				Filed

104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

* Certain schedules, appendices and exhibits have been omitted in accordance with Item 1 601 of Regulation S-K. ~~Legal~~A ~~Proceedings~~copy of any omitted schedule, appendix and/or exhibit will be furnished supplementally to the Staff of the Securities and Exchange Commission upon request.

~~Management is~~** ~~not~~This ~~aware~~exhibit ofis ~~any~~being ~~legal~~furnished ~~proceedings~~rather ~~contemplated~~than byfiled ~~any~~and ~~governmental~~shall ~~authority~~not orbe ~~any~~deemed ~~other~~incorporated ~~party~~by ~~involving~~reference usinto ~~or our properties. As of the date of this Quarterly Report, no director, officer or affiliate is (i) a party adverse to us in~~ any ~~legal proceeding~~filing, ~~or (ii) has an adverse interest to us~~ in ~~any~~accordance ~~legal~~with ~~proceedings.~~Item ~~Management~~601 ~~is not aware~~ of ~~any~~Regulation ~~other legal proceedings pending or that have been threatened against us or our properties~~S-K.

~~Item 1A. Cybersecurity~~21

~~To date,~~Table ~~the Company has not identified any cybersecurity incidents which have materially affected, or are reasonably likely to materially affect, the Company’s business strategy, results~~ of operations or financial condition. The Company has not implemented any specific policies with respect to monitoring and managing cybersecurity threats. Moreover, the Company is aware of the evolution of cybersecurity risks and is taking proactive steps by keeping up to date our information systems and educating our personnel about these risks.Contents

The Company recognizes the importance of developing, implementing, and maintaining cybersecurity measures to safeguard its information systems and protect the confidentiality, integrity, and availability of the data. The Company will be looking to adopt cybersecurity processes, technologies and controls to aid in its efforts to assess, prevent, identify and manage such risks.SIGNATURES

~~Item~~In 2.accordance ~~Unregistered~~with ~~Sales~~the Ofrequirements ~~Equity~~of ~~Securities~~the ~~and~~Exchange ~~Use~~Act, Ofthe ~~Proceeds~~registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

None

	BioScience Health Innovations Inc.

Dated: May 11, 2026	By:	/s/ Darren Lopez
		Darren Lopez
		Chief Executive Officer
		(Principal Executive Officer)

~~Item~~Pursuant 3.to ~~Defaults~~the ~~Upon~~requirements ~~Senior~~of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Not applicable.

Name	Title	Date

/s/ Darren Lopez	Principal Executive Officer and Director	May 11, 2026
Darren Lopez

~~Item 4. Mine Safety Disclosures~~22

~~Not~~ ~~applicable.~~ 1 1 0001784440 false Q1 --12-31 0001784440 2026-01-01 2026-03-31 0001784440 2026-05-08 0001784440 2026-03-31 0001784440 2025-12-31 0001784440 2025-01-01 2025-03-31 0001784440 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001784440 us-gaap:CommonStockMember 2024-12-31 0001784440 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001784440 us-gaap:RetainedEarningsMember 2024-12-31 0001784440 2024-12-31 0001784440 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0001784440 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001784440 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001784440 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001784440 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-03-31 0001784440 us-gaap:CommonStockMember 2025-03-31 0001784440 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001784440 us-gaap:RetainedEarningsMember 2025-03-31 0001784440 2025-03-31 0001784440 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0001784440 us-gaap:CommonStockMember 2025-12-31 0001784440 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001784440 us-gaap:RetainedEarningsMember 2025-12-31 0001784440 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001784440 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001784440 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0001784440 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001784440 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-03-31 0001784440 us-gaap:CommonStockMember 2026-03-31 0001784440 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001784440 us-gaap:RetainedEarningsMember 2026-03-31 0001784440 2025-01-01 2025-12-31 0001784440 2024-01-01 2024-12-31 0001784440 2025-12-01 2025-12-01 0001784440 2025-12-01 0001784440 us-gaap:RelatedPartyMember 2025-03-31 0001784440 us-gaap:RelatedPartyMember 2025-01-01 2025-03-31 0001784440 us-gaap:RelatedPartyMember 2026-03-31 0001784440 us-gaap:RelatedPartyMember 2026-01-01 2026-03-31 0001784440 srt:MinimumMember 2025-09-10 0001784440 srt:MaximumMember 2025-09-10 0001784440 2025-09-10 2025-09-10 0001784440 srt:MaximumMember 2026-03-31 0001784440 srt:MinimumMember 2026-03-31 0001784440 us-gaap:PreferredStockMember 2026-03-31 0001784440 us-gaap:SeriesAPreferredStockMember 2026-03-31 0001784440 us-gaap:SeriesAPreferredStockMember 2025-12-31 0001784440 us-gaap:SubsequentEventMember 2026-04-01 2026-05-08 xbrli:shares iso4217:USD iso4217:USD xbrli:shares notr:segment xbrli:pure

Item 5. Other Information

Not applicable.

Table of Contents

Item 6. Exhibits

Exhibit #	Exhibit Description	Incorporated By Reference			Filed or Furnished Herewith
		Form	Date	Number
3.1(a)	Articles of Incorporation	S-1	11/4/2019	3.1
3.1(b)	Amendment to Articles of Incorporation	10-K	11/26/2021	3.1B
3.2	Bylaws	S-1	11/4/2019	3.2
10.1	Stock purchase agreement dated August 29, 2022*	10-Q	08/11/2023	10.1
10.2	Stock purchase Agreement dated October 19, 2022*	10-Q	08/11/2023	10.2
10.3	Stock purchase Agreement dated December 20, 2022	10-Q	08/11/2023	10.3
31.1	Certification of Principal Executive Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a)				Filed
31.2	Certification of Principal Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a)				Filed
32.1	Certification of Principal Executive Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002				Furnished**
32.2	Certification of Principal Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002				Furnished**
101	Inline Interactive data files pursuant to Rule 405 of Regulation S-T				Filed
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

* Certain schedules, appendices and exhibits have been omitted in accordance with Item 601 of Regulation S-K. A copy of any omitted schedule, appendix and/or exhibit will be furnished supplementally to the Staff of the Securities and Exchange Commission upon request.

** This exhibit is being furnished rather than filed and shall not be deemed incorporated by reference into any filing, in accordance with Item 601 of Regulation S-K.

Table of Contents

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BioScience Health Innovations Inc.
Dated: October 27, 2025	By:	/s/ Darren Lopez
		Darren Lopez
		Chief Executive Officer
		(Principal Executive Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Name	Title	Date
/s/ Darren Lopez	Principal Executive Officer and Director	October 27, 2025
Darren Lopez

0001784440 false Q3 --12-31 0001784440 2025-01-01 2025-09-30 0001784440 2025-10-24 0001784440 2025-09-30 0001784440 2024-12-31 0001784440 us-gaap:RelatedPartyMember 2025-09-30 0001784440 us-gaap:RelatedPartyMember 2024-12-31 0001784440 2025-07-01 2025-09-30 0001784440 2024-07-01 2024-09-30 0001784440 2024-01-01 2024-09-30 0001784440 us-gaap:PreferredStockMember 2023-12-31 0001784440 us-gaap:CommonStockMember 2023-12-31 0001784440 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001784440 us-gaap:RetainedEarningsMember 2023-12-31 0001784440 2023-12-31 0001784440 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001784440 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001784440 2024-01-01 2024-03-31 0001784440 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001784440 us-gaap:PreferredStockMember 2024-03-31 0001784440 us-gaap:CommonStockMember 2024-03-31 0001784440 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001784440 us-gaap:RetainedEarningsMember 2024-03-31 0001784440 2024-03-31 0001784440 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001784440 2024-04-01 2024-06-30 0001784440 us-gaap:PreferredStockMember 2024-06-30 0001784440 us-gaap:CommonStockMember 2024-06-30 0001784440 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001784440 us-gaap:RetainedEarningsMember 2024-06-30 0001784440 2024-06-30 0001784440 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001784440 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001784440 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001784440 us-gaap:PreferredStockMember 2024-09-30 0001784440 us-gaap:CommonStockMember 2024-09-30 0001784440 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001784440 us-gaap:RetainedEarningsMember 2024-09-30 0001784440 2024-09-30 0001784440 us-gaap:PreferredStockMember 2024-12-31 0001784440 us-gaap:CommonStockMember 2024-12-31 0001784440 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001784440 us-gaap:RetainedEarningsMember 2024-12-31 0001784440 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001784440 2025-01-01 2025-03-31 0001784440 us-gaap:PreferredStockMember 2025-03-31 0001784440 us-gaap:CommonStockMember 2025-03-31 0001784440 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001784440 us-gaap:RetainedEarningsMember 2025-03-31 0001784440 2025-03-31 0001784440 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001784440 2025-04-01 2025-06-30 0001784440 us-gaap:PreferredStockMember 2025-06-30 0001784440 us-gaap:CommonStockMember 2025-06-30 0001784440 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001784440 us-gaap:RetainedEarningsMember 2025-06-30 0001784440 2025-06-30 0001784440 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001784440 us-gaap:PreferredStockMember 2025-09-30 0001784440 us-gaap:CommonStockMember 2025-09-30 0001784440 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001784440 us-gaap:RetainedEarningsMember 2025-09-30 0001784440 2024-01-01 2024-12-31 0001784440 2023-01-01 2023-12-31 0001784440 us-gaap:RelatedPartyMember bhic:AgelessHoldingsLLCMember 2025-01-01 2025-09-30 0001784440 us-gaap:RelatedPartyMember bhic:AgelessHoldingsLLCMember 2025-09-30 0001784440 us-gaap:RelatedPartyMember bhic:AgelessHoldingsLLCMember 2024-01-01 2024-09-30 0001784440 us-gaap:RelatedPartyMember bhic:AgelessHoldingsLLCMember 2024-09-30 0001784440 srt:MinimumMember 2025-09-10 0001784440 srt:MaximumMember 2025-09-10 0001784440 us-gaap:SeriesAPreferredStockMember 2025-09-30 0001784440 us-gaap:SeriesAPreferredStockMember 2024-12-31 0001784440 us-gaap:SubsequentEventMember 2025-10-01 2025-10-20 xbrli:shares iso4217:USD iso4217:USD xbrli:shares

Filing Compare · BioScience Health Innovations, Inc.